Search 

PressCise is a research project from CHalmers and University of Gothenburg aimed at developing a unique bandage. The bandage will be used for remediation including varicose vein surgery and should be easy to wrap.

Recopharma is a biotechnology company, founded in 2004. The company is based in Gothenburg, Sweden, at the Biotech Center.

Recopharma carries out activities in the field of ophthalmology, developing potential products for treatment of eye diseases. The Company has developed a unique technology, with many potential applications,  that uses mucins, which naturally occur in lacrimal fluid, where they protect, lubricate and help keep the tear film intact.

Red Glead Discovery has two main business areas: CRO services and internal early drug discovery projects. Our focus is on the development of drugs based on small molecules and peptides.

Our first-rate drug discovery services include integrated lead discovery, based on competence and long-standing experience. In-house laboratory capabilities comprise medicinal chemistry, assay development and screening, radioisotope-labelling, analytical chemistry, in vitro profiling and NMR.

An expert area is generation of chemical starting points for drug targets and to develop them into patentable lead compounds with drug-like properties and low risk profile. Our project management skills and cross-disciplinary capabilities make us a preferred partner for clients that want to develop compounds with high potential to become successful drugs.

Redoxis is a Swedish company which main competence is target validation and preclinical development of novel therapies for autoimmune diseases. Redoxis focus both on own target discovery research and professional CRO services on preclinical drug and target evaluation in animal models. Our main interest and knowledge is within rheumatoid arthritis (RA) and multiple sclerosis (MS) and we have several years of expertise of animal models for these diseases. We offer services regarding evaluation of novel drugs and therapeutic targets both in vitro, ex vivo and in vivo in animal models and we can assist in design, performance and interpretation of the results from the experiments. Our model systems are well validated and as a small company can offer flexible study design through communication with our sponsors. 

Redoxis drug development project is characterized by protected small molecules targeting target of immunological relevance that are regulated by Redoxis stimulation and of importance in CD4 T cell receptor signaling immune responses. Of primary focus are autoimmune disorders like the orphan disease Guillain-Barrés Syndrome (GBS), Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA).

SPAGO Imaging conducts research and development in the nanomedicine field with focus on diagnosis and treatment of cancer. The development is based on SPAGO's two proprietary platform technologies, IonXgel and 3PEG.

IonXgel is a unique nanomaterial and the basis for SPAGO’s novel cancer selective MRI contrast agent, SPAGO Pix. The SPAGO Pix portfolio also includes opportunities within cancer selective drug delivery for improved cancer treatment, as well as additional MR imaging indications. 

3PEG is a proprietary pegylation platform that can improve critical drug properties of small molecules, peptides and proteins, and provide e.g. increased efficacy and reduced side effects, and has therefore a broad clinical application.

SPAGO Imaging encompasses many years of experience from contrast- and pharma industry, including discovery research, early clinical- and business development.

The company was established in 2007 and is located in Lund, Sweden and employs a team of eight. SPAGO Imaging is publicly traded on the “Aktietorget” exchange in Stockholm.